Neurokinin Receptor
Dysfunction of the neurokinin receptor (NKR) system in the brain is associated with neurological disorders. NKR also referred to as tachykinin receptor belongs to the class of G-protein coupled receptor (GPCR). Three different families have been identified, namely, NK-1, NK-2 and NK-3. Among these three, NK-1 is immensely studied. The NK1R binds preferably to substance P (SP) followed by SP-like hemokinin and endokinin peptides, neurokinin A and neurokinin B. The NK1R is widely distributed throughout the immune and nervous system and regulates the functions of the gastrointestinal tract, respiratory tract, urogenital system, skin, nociceptive transmission and neurogenic inflammation. The NK1R has two isoforms: full-length form and truncated form.
The full-length NK1R has 407 amino acids, and the truncated form has 311 amino acids differing in the length of the carboxyl terminus. Amongst the NK1R isoforms identified in the human brain, the full-length form appears most common. The truncated form is spread all over peripheral tissues and the central nervous system (CNS) In cells that express the full-length NK1R, SP caused the augmented calcium level, and increased threonine phosphorylation of protein kinase C δ (PKC δ), ERK-1/2 and activation of NF-?B. The biological responses to SP-mediated through full-length and truncated NK1R are different. NK1R signaling contributes to the generation of inflammatory mediators leading to neuroinflammation. The NK1R is present in the CNS and peripheral nervous system, with SP as the ligand. However, drugs which modulate the NK1R action are not got into commercial market except for nausea. NK1R antagonists may be considered as a novel therapeutic target for treating CNS disorders.
References
1.Eapen PM, et al. Rev Neurosci. 2019;30(3):233–243.
The full-length NK1R has 407 amino acids, and the truncated form has 311 amino acids differing in the length of the carboxyl terminus. Amongst the NK1R isoforms identified in the human brain, the full-length form appears most common. The truncated form is spread all over peripheral tissues and the central nervous system (CNS) In cells that express the full-length NK1R, SP caused the augmented calcium level, and increased threonine phosphorylation of protein kinase C δ (PKC δ), ERK-1/2 and activation of NF-?B. The biological responses to SP-mediated through full-length and truncated NK1R are different. NK1R signaling contributes to the generation of inflammatory mediators leading to neuroinflammation. The NK1R is present in the CNS and peripheral nervous system, with SP as the ligand. However, drugs which modulate the NK1R action are not got into commercial market except for nausea. NK1R antagonists may be considered as a novel therapeutic target for treating CNS disorders.
References
1.Eapen PM, et al. Rev Neurosci. 2019;30(3):233–243.
GPCR/G Protein
ACAT(3)
Angiotensin Receptor(27)
Antibacterial(545)
Bombesin Receptor(13)
Bradykinin Receptor(23)
Calcium Channel(197)
cAMP(16)
Cannabinoid Receptor(88)
CaSR(18)
CGRP Receptor(18)
Chemokine Receptor(104)
Cholecystokinin Receptor(24)
CRF Receptor(14)
Dopamine Receptor(181)
Endothelin Receptor(28)
FFAR(5)
Galanin Receptor(1)
GHSR(20)
Glucagon Receptor(51)
GPCR19(9)
GPR119(3)
Hedgehog (Hh)(35)
Histamine Receptor(139)
Imidazoline Receptor(1)
Leukotriene Receptor(15)
LHR(1)
LPA Receptor(19)
Lysophospholipid Receptor(13)
mAChR(25)
MCHR(8)
Melanocortin Receptor(28)
Melatonin Receptor(7)
mGluR(11)
Motilin Receptor(4)
Neurokinin Receptor(43)
Neuropeptide Y Receptor(44)
Neurotensin Receptor(11)
Orexin Receptor(16)
Other Targets(3)
OXTR(2)
P2Y Receptor(14)
PAR(28)
Platelet-activating Factor Receptor(2)
Prostaglandin Receptor(79)
PTH Receptor(1)
S1P Receptor(35)
SGLT(26)
Somatostatin Receptor(15)
Urotensin Receptor(4)
Vasopressin Receptor(20)
Neurokinin Receptor
-
Burapitant
catalog no : M36273
cas no: 537034-22-3
Burapitant (SSR 240600) is a novel non-peptide tachykinin neurokinin 1 (NK) receptor antagonist with anti-coke oven and antidepressant activity. -
(R)-CJ 11974
catalog no : M36169
cas no: 187281-35-2
(R)-CJ 11974 is a novel non-peptide neurokinin NK1 substance P receptor antagonist with potential analgesic activity that can be used to study chemotherapy-induced vomiting. -
Ezlopitant
catalog no : M36168
cas no: 147116-64-1
Ezlopitant (CJ-11974) is a small molecule neurokinin-1-receptor (NK1) antagonist used to treat nausea, vomiting and pain. -
Rolapitant hydrochloride B
catalog no : M34929
cas no: 858102-79-1
Rolapitant (SCH619734) hydrochloride is a potent, selective, long-acting, and orally active neurokinin 1 (NK1) receptor antagonist with a K_i of 0.66 nM, which does not interact with CYP3A4 and demonstrates potent centrally-mediated anti-emetic activity in both acute and delayed ferret emesis models . -
WIN 51,708
catalog no : M34471
cas no: 144177-30-0
WIN 51,708 is a neurokinin receptor (NK1) antagonist.